These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 21536094

  • 1. The emergence of designed multiple ligands for neurodegenerative disorders.
    Geldenhuys WJ, Youdim MB, Carroll RT, Van der Schyf CJ.
    Prog Neurobiol; 2011 Sep 01; 94(4):347-59. PubMed ID: 21536094
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec 01; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders.
    Youdim MB, Buccafusco JJ.
    Trends Pharmacol Sci; 2005 Jan 01; 26(1):27-35. PubMed ID: 15629202
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Modulating self-assembly of amyloidogenic proteins as a therapeutic approach for neurodegenerative diseases: strategies and mechanisms.
    Liu T, Bitan G.
    ChemMedChem; 2012 Mar 05; 7(3):359-74. PubMed ID: 22323134
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. What's in the pipeline for the treatment of Parkinson's disease?
    Sommer DB, Stacy MA.
    Expert Rev Neurother; 2008 Dec 05; 8(12):1829-39. PubMed ID: 19086879
    [Abstract] [Full Text] [Related]

  • 14. List of drugs in development for neurodegenerative diseases. Update June 2006.
    Kwon MO, Herrling P.
    Neurodegener Dis; 2006 Dec 05; 3(3):148-86. PubMed ID: 16954701
    [No Abstract] [Full Text] [Related]

  • 15. Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases.
    Popovic N, Brundin P.
    Int J Pharm; 2006 May 18; 314(2):120-6. PubMed ID: 16529886
    [Abstract] [Full Text] [Related]

  • 16. Treatment possibilities of Alzheimer's disease.
    Miklya I, Gaszner P.
    Neuropsychopharmacol Hung; 2004 Dec 18; 6(4):200-9. PubMed ID: 15825676
    [Abstract] [Full Text] [Related]

  • 17. The brain as a target for inflammatory processes and neuroprotective strategies.
    Skaper SD.
    Ann N Y Acad Sci; 2007 Dec 18; 1122():23-34. PubMed ID: 18077562
    [Abstract] [Full Text] [Related]

  • 18. Understanding the broad-spectrum neuroprotective action profile of green tea polyphenols in aging and neurodegenerative diseases.
    Mandel SA, Amit T, Weinreb O, Youdim MB.
    J Alzheimers Dis; 2011 Dec 18; 25(2):187-208. PubMed ID: 21368374
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Clinical potential of minocycline for neurodegenerative disorders.
    Blum D, Chtarto A, Tenenbaum L, Brotchi J, Levivier M.
    Neurobiol Dis; 2004 Dec 18; 17(3):359-66. PubMed ID: 15571972
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.